DSP107

An Open-label Phase Ib Study of DSP107 for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
36 patients (estimated)
Sponsors
Kahr Medical
Tags
Antimetabolites, BCL-2 Inhibitor, Hypomethylating Agents (HMA), CD137, CD47
Trial Type
Treatment
Last Update
3 months ago
SparkCures ID
1538
NCT Identifier
NCT04937166

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.